Tinker, A.V.; Altman, A.D.; Bernardini, M.Q.; Ghatage, P.; Gien, L.T.; Provencher, D.; Salvador, S.; Doucette, S.; Oza, A.M.
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Curr. Oncol. 2022, 29, 4354-4369.
https://doi.org/10.3390/curroncol29060348
AMA Style
Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM.
A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology. 2022; 29(6):4354-4369.
https://doi.org/10.3390/curroncol29060348
Chicago/Turabian Style
Tinker, Anna V., Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, and Amit M. Oza.
2022. "A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers" Current Oncology 29, no. 6: 4354-4369.
https://doi.org/10.3390/curroncol29060348
APA Style
Tinker, A. V., Altman, A. D., Bernardini, M. Q., Ghatage, P., Gien, L. T., Provencher, D., Salvador, S., Doucette, S., & Oza, A. M.
(2022). A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology, 29(6), 4354-4369.
https://doi.org/10.3390/curroncol29060348